Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Table of Contents

Abstracts / 21st Annual Congress, Amsterdam, The Netherlands 24–28 September 2011

01 September 2011; volume 38, issue Suppl 55

  • 41. The COPD patient experience: care and management
  • 42. New insights in the treatment of idiopathic pulmonary fibrosis
  • 43. Early diagnosis in primary care
  • 44. Smoking cessation science
  • 45. Mechanisms and outcomes of infective exacerbations of COPD
  • 46. Skeletal muscle weakness in COPD: physical (in)activity and biological markers
  • 47. Macrophages and neutrophils in chronic lung disease
  • 48. Immunobiology in the transplanted lung: experimental and clinical evaluations
  • 49. Are needles really enough?
  • 50. COPD management
  • 51. Allergen immunotherapy and anti-immunoglobulin E
  • 52. Physical activity, methodology and impact
  • 53. Tuberculin skin tests, interferon-gamma release assays and beyond
  • 54. Genetic and environmental risk factors for respiratory diseases
  • 63. Mechanism and monitoring of airway diseases
  • 64. Cystic fibrosis: new aspects of diagnosis, inflammation and detecting exacerbation
  • 65. Endoscopic lung volume reduction: hype or hope?
  • 66. Altered mechanisms during exercise in disease
  • 67. Treatment of lung cancer
  • 68. Multidrug-resistant tuberculosis
  • 69. Diagnosis and predictors of COPD exacerbation
  • 70. Treatments for pulmonary hypertension in human and experimental models
  • 71. Recent developments in COPD
  • 72. Genetics of airway diseases and treatment
  • 73. Pleural diseases and pneumothorax
  • 74. Biomarkers of allergic inflammation
  • 75. The new clinical spectrum of lung diseases: from bronchi to pleura
  • 76. Innate and exogenous factors in childhood respiratory infection
  • 78. Asthma: a heterogeneous disease
  • 79. COPD management
  • 80. COPD exacerbation
  • 81. Vascular and parenchymal imaging
  • 82. From outside to inside: access to the pleura
  • 83. To stent or not to stent: interventional bronchoscopy
  • 84. Rare diffuse lung diseases
  • 85. What is new in the approach to pulmonary fibrosis?
  • 86. Experimental models and research in diffuse parenchymal lung diseases
  • 87. Quality of life and respiratory symptom management in primary care
  • 88. New mechanisms in airway disease
  • 89. COPD: human studies
  • 90. Airway smooth muscle cells and fibroblasts: cell biology
  • 91. Lung cell biology
  • 92. The ageing pulmonary interstitium
  • 93. Anti-inflammatory strategies in acute lung injury
  • 94. Drug delivery and pharmacokinetics I
  • 95. Translational models of disease
  • 96. Bronchodilators in asthma and COPD
  • 97. Asthma: control and treatment
  • 98. Monitoring exacerbations of airway diseases
  • 99. Monitoring with lung function tests in airway diseases
  • 100. Clinical parameters in airway diseases
  • 101. Animal models of airway inflammation
  • 102. Asthma: risk factors and comorbidities
  • 103. Respiratory epidemiology: genetics and modifiable risk factors
  • 104. Respiratory epidemiology: comorbidity
  • 105. Air pollution
  • 106. Mineral dusts
  • 107. Smoking cessation science and smoking-related disorders
  • 108. Smoking rate: smoking cessation interventions
  • 109. New insights in paediatric respiratory physiology
  • 110. Risk and detection of childhood asthma and allergy
  • 111. Paediatric respiratory infection: signs, symptoms and sequelae
  • 112. Paediatric epidemiology: bronchiolitis, pneumonia, asthma and spirometry in non-respiratory conditions
  • 113. Lung function today and tomorrow I
  • 114. Lung function today and tomorrow II
  • 115. Exercise tests and emerging outcomes: defining the impact of pulmonary rehabilitation
  • 116. Exacerbations and severe chronic respiratory disease: oxygen, rehabilitation, admission to hospital and palliative care
  • 117. Rehabilitation, outcome measures and effects
  • 118. Respiratory physiotherapy in the intensive care unit and on the ward: breathing exercises and respiratory muscles
  • 119. Asthma: issues in rehabilitation and physical therapy
  • 120. The eclectic world of respiratory nursing
  • 151. Mechanisms of allergic inflammation of the airways
  • 152. Dilemmas and progress in understanding childhood asthma
  • 153. Flexible bronchoscopy in the diagnosis of paediatric lung diseases
  • 154. Physiology and cardiometabolic comorbidities in obstructive sleep apnoea
  • 155. Advances in long-term noninvasive positive pressure ventilation
  • 156. Functional lung and pulmonary arterial imaging
  • 157. Epithelial cells: role in health and disease
  • 158. Exercise training: new populations, new techniques
  • 159. Biomarkers and outcomes of community-acquired pneumonia
  • 160. Progress in pathology of lung cancer
  • 161. Paediatric epidemiology: predicting outcomes of wheeze, antenatal growth, early life exposures and outcome of premature birth
  • 162. Clinical characteristics of patients with pulmonary hypertension
  • 163. Exercise assessment in different diseases
  • 164. Smoking-related disorders and smoking prevention
  • 213. Understanding the burden of chronic respiratory diseases: what decision makers need to know
  • 214. Mechanisms of acute lung injury and mesenchymal cell treatment
  • 215. Clinical application of exhaled biomarkers
  • 216. Molecular pathology and functional genomics of lung disease
  • 217. Cardio-pulmonary interactions
  • 218. Viral respiratory infections in children: causes and consequences
  • 219. Indoor hazards and respiratory disease: irritants and allergens
  • 220. Genes, environment and obstruction
  • 221. Obstructive sleep apnoea: the heart and the brain
  • 222. Comorbidities and impact on society of asthma and COPD
  • 223. Models of disease and drug actions
  • 224. Smoking-related diseases and smoking cessation
  • 225. Tuberculosis: from bench to bedside
  • 226. T-cell subsets
  • 234. Phenotyping asthma: a clue for treatments?
  • 235. Imaging in COPD
  • 236. The best abstracts in rehabilitation and chronic care 2011 (sponsored by Nutricia Advanced Medical Nutrition)
  • 237. What is new in tuberculosis immunodiagnosis?
  • 238. The burden of work-related respiratory disease: known and new end-points
  • 239. Surgery for lung cancer: pre-operative evaluation and results
  • 240. Resuscitation and ventilation in the baby and infant
  • 241. Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
  • 242. Tuberculosis in immunocompromised hosts
  • 243. Lung cancer: molecular pathology and functional genomics
  • 244. Progress in endoscopy for the diagnosis of lung cancer
  • 245. Mechanical ventilation and lung injury: new advances
  • 246. Genetic and molecular background in pulmonary fibrosis
  • 247. Advances in lung function testing from infancy to adulthood
  • 248. Acute respiratory failure
  • 249. Intensive care outcome
  • 250. Noninvasive ventilation in the acute setting: education, organisation, H1N1, paediatrics, weaning, diagnostic procedures and special considerations
  • 251. New evidence in home mechanical ventilation
  • 252. Respiratory and skeletal muscle assessment in health and disease
  • 253. Lung and airway function
  • 254. Clinical physiology for clinical problems
  • 255. Innovative methods in exercise testing
  • 256. Epidemiology, diagnosis and treatment in obstructive sleep apnoea
  • 257. Physiology and diagnostic technology in obstructive sleep apnoea
  • 258. Cardiometabolic and neurocognitive changes in obstructive sleep apnoea
  • 259. Comorbid obstructive sleep apnoea (OSA) and OSA comorbidities
  • 260. Obstructive sleep apnoea: clinical aspects I
  • 261. Treatment of human pulmonary hypertension
  • 262. Physiology of human pulmonary hypertension
  • 263. Clinical features of pulmonary hypertension
  • 264. Clinical features of pulmonary thromboembolism
  • 265. Pulmonary hypertension in hypoxic lung disease
  • 266. Treatment of pulmonary hypertension
  • 267. Chest wall trauma and airway management
  • 268. General thoracic surgery I
  • 269. Lung transplantation
  • 270. Aetiology, diagnosis and outcomes in community-acquired pneumonia
  • 271. Assessment of severity and predictors of outcomes in community-acquired pneumonia
  • 272. New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections
  • 273. Infection in the immunocompromised host: infrequent aetiologies
  • 274. Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis
  • 275. Antimicrobial treatment and resistance in lower respiratory tract infections
  • 276. Clinical tuberculosis
  • 277. Management of tuberculosis
  • 278. Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis
  • 279. Tuberculosis epidemiology and public health
  • 280. Risk assessment for tuberculosis
  • 281. Extrapulmonary tuberculosis and surgical interventions
  • 282. Pulmonary and extrapulmonary tuberculosis
  • 283. Clinical challenges in tuberculosis
  • 284. Epidemiology of lung cancer and screening
  • 285. Imaging, functional evaluation and staging for lung cancer patients
  • 286. Palliation and morbidity in lung cancer patients
  • 287. Biomarkers and other new methods for lung cancer
  • 288. Instructive clinical aspects of lung cancer
  • 289. Pleural and mediastinal malignancies: management and rare clinical cases
  • 290. Medical education
  • 320. COPD: mechanisms and biomarker
  • 321. Barrier functions in sepsis and acute lung injury
  • 322. Treatment options and tumour biology of malignant pleural mesothelioma
  • 323. COPD: burden of disease, imaging and management
  • 324. Comorbidities and management in primary care
  • 325. Noninvasive ventilation on the intensive care unit: from novel application to end of life issues
  • 326. Chest physiotherapy and breathing retraining
  • 327. Novel clinical features of acute and chronic lung diseases
  • 328. Measuring physical activity and exercise performance in chronic lung disease: implications for rehabilitation
  • 329. Role of infection in exacerbations of COPD
  • 330. Quality control in lung function and exercise-related issues
  • 331. Obstructive sleep apnoea: inflammation and metabolism
  • 332. Improving outcomes after lung transplantation
  • 333. Epithelial cell biology
  • 357. Pulmonary infections and sepsis
  • 358. E-learning
  • 359. Important new developments in paediatric respiratory physiology
  • 360. New insights in the incidence, variation and risk factors of asthma
  • 361. Growth factors and fibrogenesis: are they good, bad or both?
  • 362. Obstructive sleep apnoea in children and adults
  • 363. Sleep and weight: heavy under pressure
  • 364. Physical activity monitors: from toy to valid tool?
  • 365. Asthma: basic science and clinical studies
  • 366. Inflammation and genes in childhood asthma
  • 367. Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis
  • 368. Environmental exposure and disease mechanisms
  • 369. Experimental pulmonary hypertension
  • 370. Biomarkers and exacerbations of asthma and COPD
  • 378. Non-tuberculous mycobacteria pulmonary infections
  • 379. Early wheezing conditions in childhood
  • 380. Late-Breaking Abstracts Session: New mechanisms in airway disease
  • 381. Highlights in lung function 2011
  • 382. New treatments for airway disease
  • 383. Pathobiology of experimental pulmonary hypertension
  • 384. Outdoor air pollution studies
  • 385. Understanding disease and drug mechanisms
  • 386. Obstructive sleep apnoea as a comorbidity
  • 387. Challenges in chronic disease management: helping individuals with chronic lung disease remain stable
  • 388. Insight into mechanisms of respiratory infections
  • 389. Phenotyping and monitoring of airway diseases
  • 390. Treatment beyond inhalers: endoscopic lung volume reduction
  • 391. Molecular markers: diagnosis and management of malignant pleural effusions
  • 393. COPD diagnosis
  • 394. COPD mechanisms
  • 395. New insights in management of interstitial and vascular lung diseases
  • 396. What do individuals know about their disease? Educational needs, the psychological impact of chronic respiratory disease and health-related quality of life
  • 397. Challenges in rehabilitation: some old dilemmas revisited with some solutions?
  • 398. Imaging in oncology and infectious diseases
  • 399. The basic and the future: pure diagnostic or dedicated wavelengths play
  • 400. A little bit of everything: interventional pneumology
  • 401. Different profiles of sarcoidosis and other granulomatous disorders
  • 402. Clinical perspectives in several interstitial diseases
  • 403. Quality of diagnosis and assessment in primary care
  • 404. Recent advances in noninvasive ventilation used for treating acute respiratory failure
  • 405. Lung development and neoplasia
  • 406. COPD: clinical studies and animal cell models
  • 407. Immunology and cell biology of asthma and COPD
  • 408. Phagocytes and dendritic cells
  • 409. Cell biology of lung disease
  • 410. Novel mechanisms in lung injury
  • 411. Obstructive sleep apnoea: clinical aspects II
  • 412. Prediction of pulmonary thromboembolism
  • 413. Asthma management and response
  • 414. Drug delivery and pharmacokinetics II
  • 415. Airways disease comorbidities and general aspects
  • 416. Update on monitoring airway diseases
  • 417. Bronchial hyperresponsiveness and exhaled and sputum biomarkers
  • 418. Treatment strategies, systemic manifestations and biomarkers in airway diseases
  • 419. Diagnosis and treatment of inflammatory respiratory diseases
  • 420. Experimental modulation of airway inflammation
  • 421. Respiratory epidemiology: quality of life, therapy and socioeconomics
  • 422. Respiratory epidemiology: prevalence, incidence and remission
  • 423. Respiratory epidemiology: methods, definitions and phenotypes
  • 424. Work-related respiratory diseases and specific exposures
  • 425. Work, the environment and respiratory disease
  • 426. Anti-smoking interventions: prevention and treatment
  • 427. Epidemiology of smoking and smoking cessation interventions
  • 428. Coping and lifestyle in childhood asthma
  • 429. Biological correlates and comorbidities of childhood asthma/allergy
  • 430. Cystic fibrosis: clinical and laboratory studies
  • 431. Issues in paediatric and neonatal intensive care
  • 432. General thoracic surgery II
  • 433. Influenza A (H1N1): lessons after the epidemic
  • 434. Challenges in tuberculosis control
  • 435. Novel strategies for the diagnosis of tuberculosis
  • 436. Treatment of tuberculosis and adverse drug reactions
  • 437. Quality management for lung cancer patients
  • 460. Late-Breaking Abstracts Session: New treatments and targets for airway disease
  • 461. Innovative diagnostic methods for lung cancer
  • 462. Appropriate use of antibiotics in respiratory infections in Europe (the GRACE project)
  • 463. Biomarkers in sarcoidosis
  • 464. Access to the periphery: solitary periphery nodule
  • 466. COPD mechanisms
  • 467. Cystic fibrosis: new basic, clinical and bacteriological knowledge
  • 468. Rare lung diseases in children
  • 469. Lung cell injury and repair
  • 470. Morphological and functional imaging in obstructive airway disease
  • 471. Disease management in specific primary care populations
  • 479. Cystic fibrosis: detection and monitoring of early lung disease
  • 482. How to improve lung cancer care
  • 483. The impact of the organisation of care on costs: the role of the physician in home care
  • 484. Translational models of airway disease
  • 485. Smoking-related disorders
  • 486. Surgical options in pulmonary infections
  • 487. Severity, comorbidities and outcomes in community-acquired pneumonia
  • 488. Phenotyping airway diseases
  • 489. Continuous medical education
  • 490. Physiological basis of respiratory disease
  • 491. Molecular: pathology of infectious and inflammatory lung disease
  • 492. Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
  • 493. Role of the biomarkers in airway diseases
  • 494. Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD
  • 495. Treating childhood asthma
  • 502. Clinical approach of diffuse parenchymal lung disease
  • 503. COPD: integrated care and rehabilitation
  • 504. Innovative methods in clinical physiology
  • 506. Asthma mechanisms
  • 507. Tuberculosis in special populations
  • 508. Novel mechanisms in COPD
  • 509. Clinical features of human pulmonary hypertension
  • 510. Asthma: improving diagnosis and management for reaching better control
  • 511. The work environment in the clinic
  • 512. Obstructive sleep apnoea: physiology, diagnostic tools and technology
  • 513. Tuberculosis in pregnancy and childhood
  • 514. Integrated care and telehealth in primary care
  • 515. Mechanical ventilation and weaning
Back to top
PreviousNext
  • Table of Contents
  • Index by author

Search Within This Issue

Manage Table of content Alerts
  • Most Read
  • Twitter
Loading
  • Pulsus paradoxus
  • ERS/ATS technical standard on interpretive strategies for routine lung function tests
  • European Respiratory Society guidelines for the diagnosis of asthma in adults
  • ERS clinical practice guidelines on treatment of sarcoidosis
  • The association between SARS-CoV-2 RT-PCR cycle threshold and mortality in a community cohort
More...

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society